Pressure piles on Amgen after EU pulls Tavneos, flags ‘serious breaches’ in pivotal study

Sponsors of the pivotal study behind Amgen’s rare disease drug Tavneos saw unblinded findings for the drug and re-adjudicated data from nine patients to make the drug seem effective, according to European regulators.